US Bancorp’s CureVac CVAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-919
| Closed | -$4.15K | – | 4202 |
|
|
2025
Q4 | $4.15K | Sell |
919
-758
| -45% | -$3.88K | ﹤0.01% | 3598 |
|
|
2025
Q3 | $9.04K | Hold |
1,677
| – | – | ﹤0.01% | 3352 |
|
|
2025
Q2 | $9.11K | Sell |
1,677
-1,824
| -52% | -$7.23K | ﹤0.01% | 3462 |
|
|
2025
Q1 | $9.7K | Buy |
3,501
+1,336
| +62% | +$4.65K | ﹤0.01% | 3445 |
|
|
2024
Q4 | $7.38K | Sell |
2,165
-411
| -16% | -$1.19K | ﹤0.01% | 3530 |
|
|
2024
Q3 | $7.57K | Sell |
2,576
-218
| -8% | -$718 | ﹤0.01% | 3453 |
|
|
2024
Q2 | $9.5K | Buy |
2,794
+183
| +7% | +$599 | ﹤0.01% | 3324 |
|
|
2024
Q1 | $7.91K | Sell |
2,611
-1,435
| -35% | -$5.04K | ﹤0.01% | 3410 |
|
|
2023
Q4 | $17K | Buy |
4,046
+940
| +30% | +$5.1K | ﹤0.01% | 3125 |
|
|
2023
Q3 | $21.2K | Sell |
3,106
-931
| -23% | -$8.22K | ﹤0.01% | 2851 |
|
|
2023
Q2 | $42.1K | Buy |
4,037
+344
| +9% | +$3.08K | ﹤0.01% | 2594 |
|
|
2023
Q1 | $25.7K | Buy |
3,693
+1,189
| +47% | +$10.4K | ﹤0.01% | 2860 |
|
|
2022
Q4 | $15.1K | Buy |
2,504
+1,433
| +134% | +$10.6K | ﹤0.01% | 3139 |
|
|
2022
Q3 | $9K | Sell |
1,071
-3,333
| -76% | -$38.9K | ﹤0.01% | 3392 |
|
|
2022
Q2 | $60K | Sell |
4,404
-3,719
| -46% | -$61.5K | ﹤0.01% | 2481 |
|
|
2022
Q1 | $159K | Buy |
8,123
+665
| +9% | +$13.3K | ﹤0.01% | 2063 |
|
|
2021
Q4 | $256K | Buy |
7,458
+2,150
| +41% | +$86.5K | ﹤0.01% | 1856 |
|
|
2021
Q3 | $289K | Buy |
+5,308
| New | +$320K | ﹤0.01% | 1794 |
|
US Bancorp's CVAC Position: Q1 2026 in Review
US Bancorp sold out of CureVac (CVAC) in Q1 2026, closing a stake of 919 shares — an estimated $4.15K sold.
US Bancorp first reported a position in CVAC in Q3 2021 and held it in 18 quarters. The position peaked at $289K in Q3 2021. 0 funds tracked by Wall St. Rank hold CVAC as of Q1 2026.
- US Bancorp reported no remaining CureVac position as of Q1 2026 after selling out during the quarter.
- US Bancorp sold 919 CureVac shares in Q1 2026, an estimated $4.15K.
- US Bancorp first reported a position in CureVac in Q3 2021 and held it in 18 quarters.
- US Bancorp's CureVac position peaked at $289K in Q3 2021.
- 0 funds tracked by Wall St. Rank held CureVac as of Q1 2026.
Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.